3 Diversified FMCG, Exhibition Centre and Pharmacy Chain Stocks With a Strong Future Roadmap: ITC, Nesco and Medplus Health Services
- October 16, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
ITC Rs 263.90, P/E 15.77. Nesco Rs 1,048.20, P/E 17.39. Medplus Rs 612.80, P/E 36.06. Closing prices of 14 Oct 2026.
Quick Answer
Diversified FMCG, exhibition centre and pharmacy chain stocks with the clearest long-term roadmaps today include ITC in cigarettes, packaged foods, personal care, paperboards, hotels and agri products, Nesco in exhibition and convention space at the Bombay Exhibition Centre along with an IT park and Medplus in a pharmacy retail chain with stores across several states. FY26 revenue growth was 4.4% at ITC, 20.0% at Nesco and 12.6% at Medplus. P/E stands at 15.77 for ITC (industry 34.85), 17.39 for Nesco (industry 32.08) and 36.06 for Medplus (industry 66.59). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Diversified FMCG, exhibition centre and pharmacy chain stocks give investors exposure to consumer goods, event space and pharmacy retail that households and businesses use. Sales volumes, event bookings and store additions decide how much of that demand turns into profit.
This list covers three diversified FMCG, exhibition centre and pharmacy chain stocks: ITC for cigarettes, packaged foods, personal care, paperboards, hotels and agri products, Nesco for exhibition and convention space at the Bombay Exhibition Centre along with an IT park and Medplus Health Services for a pharmacy retail chain with stores across several states. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Diversified FMCG, Exhibition Centre and Pharmacy Chain Stocks?
Diversified FMCG, exhibition centre and pharmacy chain stocks are shares of companies that make and sell products that households and businesses buy. Results depend on sales volumes, brand strength and input costs, so margins and cash flow separate the stronger names.
Diversified FMCG, Exhibition Centre and Pharmacy Chain Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three diversified FMCG, exhibition centre and pharmacy chain stocks as of the 14 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| ITC | 263.90 | 318,338 | 15.77 | 34.85 | 28.53% | 0.03 |
| Nesco | 1,048.20 | 7,243 | 17.39 | 32.08 | 13.77% | 0.09 |
| Medplus Health Services | 612.80 | 7,589 | 36.06 | 66.59 | 11.12% | 0.72 |
Among consumer stocks, all three trade at a discount to their industry P/E multiples.
Why Do Diversified FMCG, Exhibition Centre and Pharmacy Chain Stocks Have a Strong Roadmap in India?
Diversified FMCG, exhibition centre and pharmacy chain stocks have a strong roadmap in India because wider consumer brands, a busy trade show calendar and pharmacy store growth keep adding customers for these firms. Three drivers stand out.
- Brand spread: Packaged foods and personal care reach more homes.
- Trade shows: Exhibitions and conventions fill large venues.
- Pharmacy reach: Chains add stores and private label products.
ITC: Several Businesses Anchor the Roadmap
ITC’s roadmap rests on cigarettes, packaged foods, personal care, paperboards, hotels and agri products, with several businesses supporting steady cash flow.
Revenue grew from Rs 62,504.44 crore in FY22 to Rs 81,294.27 crore in FY26, a 30.1% rise, and FY26 revenue was 4.4% higher than FY25. FY26 net profit rose 4.9% to Rs 21,018.15 crore. Over four years, net profit rose from Rs 15,503.13 crore in FY22 to Rs 21,018.15 crore. In Q1 FY27, revenue grew 26.7% to Rs 30,179.01 crore. Operating margin was 33.18% in FY26.
Debt to equity is 0.03 and return on equity is 28.53%. FY26 operating cash flow was Rs 18,464.31 crore against capital expenditure of Rs 2,182.89 crore. At a P/E of 15.77 against an industry P/E of 34.85, the stock trades below its industry multiple.
What to watch: The P/E of 15.77 against an industry P/E of 34.85 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
Nesco: Exhibition Space and Leasing Drive the Pipeline
Nesco’s roadmap rests on exhibition and convention space at the Bombay Exhibition Centre along with an IT park, with event bookings and leasing income supporting revenue.
Revenue grew from Rs 382.41 crore in FY22 to Rs 1,037.50 crore in FY26, a 171.3% rise, and FY26 revenue was 20.0% higher than FY25. FY26 net profit rose 10.0% to Rs 412.74 crore. Over four years, net profit rose from Rs 189.17 crore in FY22 to Rs 412.74 crore. In Q1 FY27, revenue grew 15.3% to Rs 255.40 crore, and net profit rose 4.0% to Rs 99.96 crore. Operating margin was 63.29% in FY26.
Debt to equity is 0.09 and return on equity is 13.77%. FY26 operating cash flow was Rs 387.79 crore against capital expenditure of Rs 322.28 crore. Nesco paid a dividend of Rs 7 per share for FY26, a yield of 0.68%. At a P/E of 17.39 against an industry P/E of 32.08, the stock trades below its industry multiple.
What to watch: The P/E of 17.39 against an industry P/E of 32.08 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
Medplus Health Services: Pharmacy Retail Stores Anchor the Roadmap
Medplus’ roadmap rests on a pharmacy retail chain with stores across several states, with store expansion supporting revenue.
Revenue grew from Rs 3,810.64 crore in FY22 to Rs 6,963.79 crore in FY26, an 82.7% rise, and FY26 revenue was 12.6% higher than FY25. FY26 net profit rose 46.2% to Rs 219.61 crore. Over four years, net profit rose from Rs 94.72 crore in FY22 to Rs 219.61 crore. In Q1 FY27, revenue grew 21.9% to Rs 1,899.43 crore. Operating margin was 9.85% in FY26.
Debt to equity is 0.72 and return on equity is 11.12%. FY26 operating cash flow was Rs 495.58 crore against capital expenditure of Rs 123.03 crore. At a P/E of 36.06 against an industry P/E of 66.59, the stock trades below its industry multiple.
What to watch: Net profit margin is only 3.2%, so small cost changes move earnings.
Best Diversified FMCG, Exhibition Centre and Pharmacy Chain Stocks in India: ITC vs Nesco vs Medplus on Key Financials
Among the best diversified FMCG, exhibition centre and pharmacy chain stocks in India, ITC leads on Q1 FY27 revenue growth and return on equity; Nesco leads on FY26 revenue growth and FY26 operating margin; Medplus leads on FY26 net profit growth. The table puts the numbers side by side.
| Metric | ITC | Nesco | Medplus |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 81,294.27 | 1,037.50 | 6,963.79 |
| FY26 revenue growth | 4.4% | 20.0% | 12.6% |
| FY26 net profit (Rs Cr) | 21,018.15 | 412.74 | 219.61 |
| FY26 net profit growth | 4.9% | 10.0% | 46.2% |
| FY26 operating profit margin | 33.18% | 63.29% | 9.85% |
| Q1 FY27 revenue growth (YoY) | 26.7% | 15.3% | 21.9% |
| Return on equity | 28.53% | 13.77% | 11.12% |
| P/E ratio | 15.77 | 17.39 | 36.06 |
| Debt to equity | 0.03 | 0.09 | 0.72 |
| FY26 operating cash flow (Rs Cr) | 18,464.31 | 387.79 | 495.58 |
Consumer earnings follow sales volumes, brand strength and input costs, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Diversified FMCG, Exhibition Centre and Pharmacy Chain Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen diversified FMCG, exhibition centre and pharmacy chain stocks and shortlist diversified FMCG, exhibition centre and pharmacy chain stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and cash flow together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Risks to Consider Before Investing in Diversified FMCG, Exhibition Centre and Pharmacy Chain Stocks
- Consumer demand: Spending patterns can shift sales between quarters.
- Input costs: Changes in raw material prices can affect margins.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track ITC, Nesco and Medplus live.
Final Take: Which Stock Has the Strongest Roadmap?
These three consumer stocks cover consumer brands, exhibition space and pharmacies. ITC leads on Q1 FY27 revenue growth and return on equity; Nesco leads on FY26 revenue growth and FY26 operating margin; Medplus leads on FY26 net profit growth.
Across diversified FMCG, exhibition centre and pharmacy chain stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the diversified FMCG, exhibition centre and pharmacy chain stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Diversified FMCG, Exhibition Centre and Pharmacy Chain Stocks
Which are the best diversified FMCG, exhibition centre and pharmacy chain stocks in India with a strong roadmap?
Ans. ITC, Nesco and Medplus Health Services stand out for their roadmaps in consumer brands, exhibition space and pharmacies. FY26 revenue growth was 4.4% at ITC, 20.0% at Nesco and 12.6% at Medplus, and return on equity ranges from 11.12% to 28.53%.
Is ITC a good stock to buy now?
Ans. ITC has a debt to equity ratio of 0.03, a return on equity of 28.53% and a P/E of 15.77 against an industry P/E of 34.85. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of ITC, Nesco and Medplus?
Ans. The P/E ratio is 15.77 for ITC (industry 34.85), 17.39 for Nesco (industry 32.08) and 36.06 for Medplus (industry 66.59). All of them trade below the industry multiple.
Which of these diversified FMCG, exhibition centre and pharmacy chain stocks has the highest return on equity?
Ans. ITC has the highest return on equity at 28.53%, followed by Nesco at 13.77% and Medplus Health Services at 11.12%.
What are the risks of investing in diversified FMCG, exhibition centre and pharmacy chain stocks?
Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.
How did ITC, Nesco and Medplus perform in Q1 FY27?
Ans. ITC reported revenue of Rs 30,179.01 crore, up 26.7% year on year. Nesco reported revenue of Rs 255.40 crore, up 15.3% year on year, and net profit rose 4.0% to Rs 99.96 crore. Medplus Health Services reported revenue of Rs 1,899.43 crore, up 21.9% year on year.
Do diversified FMCG, exhibition centre and pharmacy chain stocks pay dividends?
Ans. Nesco pays dividends. The dividend yield is 0.68% for Nesco, based on dividends declared for FY26.
How can I invest in diversified FMCG, exhibition centre and pharmacy chain stocks in India?
Ans. You can buy diversified FMCG, exhibition centre and pharmacy chain stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
